The role of the cerebellum in movement and cognition
The aim of this study is to characterize how Ataxia impacts motor control and certain aspects of cognition (such as language and decision making).
Link to Enroll: http://ivrylab.berkeley.edu/participate.html
About the Study
Eligible Ataxia Types
All individuals with Cerebellar Ataxia
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
10/31/2024
Estimated Completion Date
10/31/2026
IRB Approval #
2016-02-8439
Location(s)
Cognition and Action Laboratory
2121 Berkeley Way
Berkeley, CA
Contact Information
Rich Ivry
ivrylab@berkeley.edu
510-326-6658
Sabrina Abram
abramsabrina@berkeley.edu
341-688-0661
What does participation in the study entail?
This is a on-going project. If you sign up, you will be contacted for an initial on-line interview to determine eligibility. Eligible participants will be contacted at future dates and invited to participate in particular studies. Compensation is provided for all sessions, including the initial interview.
What are the potential benefits for participants?
There are no direct benefits to you from participating in the study.
What are the potential risks for participants?
The tasks pose no risks although they may be mentally challenging.
Is there financial compensation?
Yes. $25 per hour.
Is there travel reimbursement?
Yes. Cost of fuel and travel time.
Who is eligible?
All individuals with Cerebellar Ataxia.
Additional Information or Resources
Link to Enroll: http://ivrylab.berkeley.edu/participate.html
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
